Novel antimicrobial-resistant bacteria among patients requiring chronic hemodialysis

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 2, 2012, Pages 211-215

  Snyder, Graham M ^a   D'Agata, Erika M C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

antimicrobial resistance; infection prevention; multidrug resistant Gram negative bacteria; Staphylococcus aureus; vancomycin resistant enterococci

Indexed keywords

BETA LACTAMASE; CEFTAZIDIME; CHLORHEXIDINE; CIPROFLOXACIN; GENTAMICIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; PSEUDOMONIC ACID; RIFAMPICIN; SULTAMICILLIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL STRAIN; BLOODSTREAM INFECTION; CLOSTRIDIUM DIFFICILE; COHORT ANALYSIS; DIARRHEA; DISEASE SURVEILLANCE; DRUG RESISTANCE; GENE TRANSFER; GRAM NEGATIVE BACTERIUM; HEALTH CARE; HEALTH CARE PERSONNEL; HEMODIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NEUROTOXICITY; OUTPATIENT DEPARTMENT; PATIENT CARE; PATIENT COMPLIANCE; PERSONAL HYGIENE; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

BETA-LACTAM RESISTANCE; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROCOCCUS; GRAM-NEGATIVE BACTERIA; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RENAL DIALYSIS; VANCOMYCIN RESISTANCE;

EID: 84857048248     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328350089b     Document Type: Review

References (37)

1. US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive Diseases; 2010.
2. Kallen AJ, Arduino MJ, Patel PR. Preventing infections in patients undergoing hemodialysis. Expert Rev Anti Infect Ther 2010; 8:643-655. Outlines interventions to prevent infections among patients receiving chronic hemodialysis, including data supporting these interventions.
3. Fitzgibbons LN, Puls DL, Mackay K, Forrest GN. Management of Gram-positive coccal bacteremia and hemodialysis. Am J Kidney Dis 2011; 57:624-640.
4. Patel PR, Kallen AJ, Arduino MJ. Epidemiology, surveillance, and prevention of bloodstream infections in hemodialysis patients. Am J Kidney Dis 2010; 56:566-577.
5. Barnes S, Concepcion D, Felizardo G, et al. Guide to the elimination of infections in hemodialysis: APIC elimination guide 2010. http://www.apic. org/Content/NavigationMenu/PracticeGuidance/APICEliminationGuides/ APIC-Hemodialysis-web.pdf. [Accessed 14 September 2011]
6. Centers for Disease Control and Prevention. Invasive methicillin- resistant Staphylococcus aureus infections among dialysis patients: United States, 2005. MMWR Morb Mortal Wkly Rep 2007; 56:197-199.
7. Alexander EL, Morgan DJ, Kesh S, et al. Prevalence, persistence, and microbiology of Staphylococcus aureus nasal carriage among hemodialysis outpatients at amajorNewYorkHospital. Diagn Microbiol InfectDis2011; 70:37-44.
8. Johnson LB, Jose J, Yousif F, et al. Prevalence of colonization with communityassociated methicillin-resistant Staphylococcus aureus among end-stage renal disease patients and healthcare workers. Infect Control Hosp Epidemiol 2009; 30:4-8.
9. Patel G, Jenkins SG, Mediavilla JR, et al. Clinical and molecular epidemiology of methicillin-resistant Staphylococcus aureus among patients in an ambulatory hemodialysis center. Infect Control Hosp Epidemiol 2011; 32:881-888. This thorough study of the epidemiology of MRSA in the outpatient hemodialysis setting describes MRSA prevalence, risk factors for carriage, and incidence rates of new carriage and infection.
10. Mermel LA, Eells SJ, Acharya MK, et al. Quantitative analysis and molecular fingerprinting of methicillin-resistant Staphylococcus aureus nasal colonization in different patient populations: A prospective, multicenter study. Infect Control Hosp Epidemiol 2010; 31:592-597.
11. Lautenbach E, Nachamkin I, Hu B, et al. Surveillance cultures for detection of methicillin-resistant Staphylococcus aureus: Diagnostic yield of anatomic sites and comparison of provider-And patient-collected samples. Infect Control Hosp Epidemiol 2009; 30:380-382.
12. Mera RM, Suaya JA, Amrine-Madsen H, et al. Increasing role of Staphylococcus aureus and community-Acquired methicillin-resistant Staphylococcus aureus infections in the United States: A 10-year trend of replacement and expansion. Microb Drug Resist 2011; 17:321-328.
13. D'Agata EM, Webb GF, Horn MA, et al. Modeling the invasion of communityacquired methicillin-resistant Staphylococcus aureus into hospitals. Clin Infect Dis 2009; 48:274-284.
14. Chua K, Laurent F, Coombs G, et al. Antimicrobial resistance: Not communityassociated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA-its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis 2011; 52:99-114. An excellent review of community-Acquired methicillin-resistant S. aureus.
15. US Renal Data System. USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009.
16. Kallen AJ, Jernigan JA, Patel PR. Decolonization to prevent infections with Staphylococcus aureus in patients undergoing hemodialysis: A review of current evidence. Semin Dial 2011; 24:533-539. Details the evidence to date, including advantages and disadvantages, of MRSA decolonization therapy among patients receiving CHD.
17. Hebert C, Robicsek A. Decolonization therapy in infection control. Curr Opin Infect Dis 2010; 23:340-345.
18. Lee BY, Song Y, McGlone SM, et al. The economic value of screening haemodialysis patients for methicillin-resistant Staphylococcus aureus in the USA. Clin Microbiol Infect 2011; 17:1717-1726.
19. Teo BW, Low SJ, Ding Y, et al. High prevalence of mupirocin-resistant staphylococci in a dialysis unit where mupirocin and chlorhexidine are routinely used for prevention of catheter-related infections. J Med Microbiol 2011; 60:865-867.
20. Lu PL, Tsai JC, Chiu YW, et al. Methicillin-resistant Staphylococcus aureus carriage, infection and transmission in dialysis patients, healthcare workers and their family members. Nephrol Dial Transplant 2008; 23: 1659-1665.
21. Atta MG, Eustace JA, Song X, et al. Outpatient vancomycin use and vancomycin-resistant enterococcal colonization in maintenance dialysis patients. Kidney Int 2001; 59:718-724. (Pubitemid 32157937)
22. Pop-Vicas A, Strom J, Stanley K, D'Agata EM. Multidrug-resistant Gramnegative bacteria among patients who require chronic hemodialysis. Clin J Am Soc Nephrol 2008; 3:752-758.
23. Grabsch EA, Burrell LJ, Padiglione A, et al. Risk of environmental and healthcare worker contamination with vancomycin-resistant enterococci during outpatient procedures and hemodialysis. Infect Control Hosp Epidemiol 2006; 27:287-293.
24. Park I, Park RW, Lim SK, et al. Rectal culture screening for vancomycinresistant enterococcus in chronic haemodialysis patients: False-negative rates and duration of colonisation. J Hosp Infect 2011; 79:147-150.
25. Moellering RC Jr. NDM-1: A cause for worldwide concern. N Engl J Med 2010; 363:2377-2379.
26. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: Epidemiology and prevention. Clin Infect Dis 2011; 53: 60-67. This review covers the essential information on carbapenemase-producing organisms, including their emergence, risk factors for acquisition and infection, and methods of prevention.
27. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2011 [Epub ahead of print].
28. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007; 55:254-259. (Pubitemid 47244918)
29. Rodriguez-Bano J, Picon E, Gijon P, et al. Community-onset bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: Risk factors and prognosis. Clin Infect Dis 2010; 50:40-48.
30. Bush K, Fisher JF. Epidemiological expansion, structural studies and clinical challenges of new beta-lactamases from Gram-negative bacteria. Annu Rev Microbiol 2011; 65:455-478.
31. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: No ESKAPE! an update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
32. Saely S, Kaye KS, Fairfax MR, et al. Investigating the impact of the definition of previous antibiotic exposure related to isolation of extended spectrum betalactamase-producing Klebsiella pneumoniae. Am J Infect Control 2011; 39:390-395.
33. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 2001; 50:1-43.
34. Centers for Disease Control and Prevention. Guide to infection prevention for outpatient settings: Minimum expectations for safe care, 2011. http:// www.cdc.gov/HAI/settings/outpatient/outpatient-care-guidelines.html. [Accessed 13 July 2011]
35. Arenas MD, Sanchez-Paya J, Barril G, et al. A multicentric survey of the practice of hand hygiene in haemodialysis units: Factors affecting compliance. Nephrol Dial Transplant 2005; 20:1164-1171. (Pubitemid 40862106)
36. Shimokura G, Weber DJ, Miller WC, et al. Factors associated with personal protection equipment use and hand hygiene among hemodialysis staff. Am J Infect Control 2006; 34:100-107.
37. Scheithauer S, Eitner F, Mankartz J, et al. Improving hand hygiene compliance rates in the haemodialysis setting: More than just more hand rubs. Nephrol Dial Transplant 2011 [Epub ahead of print]. A detailed study on the effect of improved infection control operating procedures on rates of hand hygiene compliance.